We'd appreciate your feedback. Send feedback Subscribe to our newsletters and alerts


Annals of Pharmacy Practice and Pharmacotherapy

2025 Volume 5

Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Infections in Patients with and Without Diabetes Mellitus: A Hospital-Based Comparative Study


, , ,
  1. Department of Clinical Pharmacy and Pharmaceutical Care, Faculty of Pharmacy, University of Granada, Granada, Spain.
  2. Department of Medication Therapy and Pharmacotherapeutics, Faculty of Medicine, University of Seville, Seville, Spain.
Abstract

To evaluate MRSA infections with a specific focus on heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) among patients with and without diabetes mellitus, and to assess differences between these two populations.Isolated S. aureus strains from diabetic and non-diabetic inpatients across four tertiary hospitals in Coastal Karnataka (South India) were assessed for methicillin resistance and enrolled in the study. Patient-related demographic and clinical information was obtained through a standardized data collection form. Antimicrobial susceptibility testing was conducted using the Kirby–Bauer disk diffusion method. Detection of macrolide–lincosamide–streptogramin B (MLSb) resistance was performed using the D-test. Vancomycin minimum inhibitory concentrations were measured by agar dilution. MRSA isolates were further evaluated for heterogeneous vancomycin-intermediate S. aureus (hVISA) using vancomycin screening agar, with confirmation by population analysis profile–area under the curve (PAP-AUC). Statistical evaluation was performed using the chi-square test, and all analyses were conducted in SPSS version 29.0.Among 665 S. aureus isolates, 220 (33.1%) were identified as MRSA. Of these, 122 (55.5%) originated from diabetic patients, while 98 (44.5%) were from non-diabetic patients. No significant differences in antimicrobial resistance profiles were observed between MRSA isolates from the two patient groups. However, MRSA-associated foot infections and osteomyelitis were significantly more frequent in diabetic patients. Among the 220 MRSA isolates, 14 (6.4%) were classified as hVISA. The prevalence of hVISA was 9.0% in isolates from diabetic patients and 3.1% in those from non-diabetic patients; however, this difference did not reach statistical significance. Overall, 6.4% of all MRSA isolates were classified as hVISA. The likelihood of hVISA was about three times higher in patients with diabetes than in those without. These results underscore the need to target screening for hVISA among MRSA strains, especially in diabetic individuals.


How to cite this article
Vancouver
Gonzalez M, Ruiz J, Torres L, Ruiz E. Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Infections in Patients with and Without Diabetes Mellitus: A Hospital-Based Comparative Study. Ann Pharm Pract Pharmacother. 2025;5:154-61. https://doi.org/10.51847/4EcoYN8Z8x
APA
Gonzalez, M., Ruiz, J., Torres, L., & Ruiz, E. (2025). Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Infections in Patients with and Without Diabetes Mellitus: A Hospital-Based Comparative Study. Annals of Pharmacy Practice and Pharmacotherapy, 5, 154-161. https://doi.org/10.51847/4EcoYN8Z8x
Articles
Therapeutic Approaches to Facilitating Expulsion of Distal Ureteric Stones
Annals of Pharmacy Practice and Pharmacotherapy
Vol 2 , 2022 | Ravindra Ambardekar
Evaluation of Antidiabetic Drug Prescribing Practices in Primary Care Clinics in Rural South India
Annals of Pharmacy Practice and Pharmacotherapy
Vol 3 , 2023 | Kumutha Theivasigamani
Development of an RP-HPLC Method for Dapagliflozin and Metformin HCL Analysis
Annals of Pharmacy Practice and Pharmacotherapy
Vol 1 , 2021 | Khagga Bhavyasri
Comparative Evaluation of Oral Wound Dressing Materials: A Comprehensive Clinical Review
Annals of Pharmacy Practice and Pharmacotherapy
Vol 4 , 2024 | Maria Pia Ferraz
Evaluation of Antibiotic Use and Financial Costs in University Hospital Intensive Care Units
Annals of Pharmacy Practice and Pharmacotherapy
Vol 4 , 2024 | Viviana Hodoșan

About GalaxyPub

Find out more

Established in 2019, Galaxy Publication stands as a global academic publishing house focused on advancing scholarly work across medicine, nursing, and health sciences. Through its network of peer-reviewed journals, the organization brings together original research and academic contributions from scholars around the world, creating a shared space for knowledge exchange and intellectual collaboration.